November 9, 2023 11:09 AM ESTUpdated November 10, 03:48 PM
News Briefing

In­tel­lia plans to file IND for AATD tri­al next year; As­cid­i­an rais­es $40M

Jaimy Lee

Deputy Editor

Lei Lei Wu

News Reporter

In­tel­lia aims to start AATD tri­al next year: The gene edit­ing com­pa­ny an­nounced Thurs­day that it plans to file an ap­pli­ca­tion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

Will CRISPR mat­ter?

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

Pfiz­er CEO says op­por­tu­ni­ties with Trump ‘clear­ly out­weigh’ the risks for phar­ma

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times